Lupin's Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch Health

Global pharma major, Lupin Limited (Lupin) announced today that its wholly owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.

As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol™, Melleril™ and Dalmadorm™ for Central Nervous System related conditions, Bacrocin™, Glyquin™, Solaquin™, Oxipelle™ and Efurix™ as topical oncological treatments, and Cuprimine™ for the treatment of Wilson's disease. This move reinforces our commitment to making healthcare solutions accessible to all patients.

"The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness," said Alexandre Franca, Managing Director, MedQuímica. "This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market."

Shares of Lupin Limited was last trading in BSE at Rs. 733.70 as compared to the previous close of Rs. 719.45. The total number of shares traded during the day was 27981 in over 1170 trades.

The stock hit an intraday high of Rs. 735.00 and intraday low of 715.60. The net turnover during the day was Rs. 20279911.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 MedQuimica Brazil Acquisition